Site Searches

1 search

SearchProtocolStatusSitesOwnerLast runActions

CDK4/6 Inhibitor — HR+/HER2− Metastatic Breast Cancer (Phase 3)

US oncology sites with CDK4/6 inhibitor trial experience in HR+/HER2− metastatic breast cancer, weighted toward centers active in older-adult populations.

NCT06377852

Ryght Demo

Complete
158 / 1801

Target: 158 Tier 1

You

1 run

v1 · 2026-05-06